Please wait...

You selected inventions in category Life Sciences

  • A NOVEL ROUTE OF THE CMK-3 CARBON REPLICA SYNTHESISA NOVEL ROUTE OF THE CMK-3 CARBON REPLICA...
      Preview
      Description

      The subject of the offer is an innovative, environmentally friendly method for obtaining of CMK-3 carbon replica, which may be a material useful in various catalytic and sorption processes as well as electrochemical applications. The method has a high potential for industrial application, and its use can significantly improve the production of high-ordered carbon materials with high surface area.

      Full details Contact close
    • NEW PYRROLE DERIVATIVES AND METHOD FOR THEIR SYNTHESISNEW PYRROLE DERIVATIVES AND METHOD FOR THEIR...
        Preview
        Description

        The subject of the offer are new pyrrole derivatives and the method of their preparation. The compounds may be used in pharmaceutical industry, in the synthesis of novel magnetic materials, polymers or in the synthesis of mesoporous compounds - MOF - as bridging units.

        Full details Contact close
      • SYNTHESIS OF HIGHLY DISPERSED OXIDE CATALYSTS ON THE BASE OF EXFOLIATED CLAYSSYNTHESIS OF HIGHLY DISPERSED OXIDE CATALYSTS ON...
          Preview
          Description

          The subject of the offer is a novel, affordable and environmentally friendly method of synthesis of oxide catalysts with high surface area dispersed on aluminosilicate supports. The method may be applied in the production of catalysts for many processes, such as dehydrogenation and oxidation of hydrocarbons or environment pollutants removal - nitrogen oxides reduction and oxidation of volatile organic compounds, in which co-existence of acidic and redox active surface sites plays an important role.

          Full details Contact close
        • NEW METHOD OF RNA VIRUSES IDENTIFICATION IN VIROLOGICAL DIAGNOSTICSNEW METHOD OF RNA VIRUSES IDENTIFICATION IN...
            Preview
            Description

            The subject of the offer is a new method of RNA viruses identification, which may be applied for detection of known RNA viruses and their variants, as well as for detection of new RNA viruses, which may not be identified by standard methods. The offered method may also be used for the amplification of fragments of RNA, which may find an application in faster and more accurate diagnosis of the RNA viruses infections.

            Full details Contact close
          • Projec-patent-OsteoporosisProjec-patent-Osteoporosis
              Preview
              Description

              BIODEX:500mg
              Patent claim BIODEX: calcium clusters (calcium peptide complexes) with modified calcium clusters (calcium peptide complexes)- with enhanced biochemical and biological features, that are extracted by non-chemical, patented process is handled by microscopic particles and they are absorbed by the body fast. As a result, is obtained and a mixture of calcium clusters (calcium peptide complexes), including a group of 27microelements: mainly copper, iron, manganese, molybdenum, phosphorus, sulfur, zinc, silicon and others, which are essential to the biochemical processes in the body, high-speed impact (both preventive and curative) on bone, restore bone density and bone metabolism, regulated it to normal levels. BIODEX meets the most stringent regulations for purity of the products in terms of lead and heavy metals.

              Full details Contact close
            • Oxygen Carrying Perfusate for Organ TransplantationOxygen Carrying Perfusate for Organ...
                Preview
                Description

                This artificial red cell does not have pathogen and blood type antigen, and can be stored at room temperatures for years. Safety and efficacy as a resuscitative fluid for hemorrhagic shock and prime fluid for extracorporeal membrane oxygenation (ECMO) are confirmed in preclinical studies. It is expected that the artificial red cell can be utilized temporally for improving storage condition of organ transplant. The artificial red cell is expected to supply oxygen at an appropriate temperature, like does erythrocyte, from the beginning of resection of an organ from a donor and during the transportation to a recipient in a remote hospital, and it can avoid ischemia reperfusion injury and cold-induced injury.

                Features and Advantages:
                * Encapsulates a concentrated Hb solution within a phospholipid vesicle
                * Utilizable without worrying about infection and blood type mismatching
                * Indicates high biocompatibility
                * Storable for over years at room temperature
                * Mass production available

                Possible Applications:
                * Perfusate for Organ Transplantation
                * Prime fluid for ECMO
                * Fluid resuscitation, fluid replacement

                Full details Contact close
              • Novel Antiprotozoal AgentNovel Antiprotozoal Agent
                  Preview
                  Description

                  The technology relates to a novel compound having antiprotozoal activity, which is particularly preferred as an antileishmania agent. The agent has a similar activity level as the amphotericin B which is one of antileishmania drugs currently used. Furthermore, the agent shows low cytotoxic effect. Since the backbone of the agent wholly differs from that of the amphotericin B, it is suggested that the mode of action is also different. This indicates that this agent can be second-line drug when the drug-resistant strains appear.

                  Features and Advantages:
                  * Xenicane diterpenes from Cnidaria
                  * Exhibit strong antileishmanial activity against Leishmania Amazonensis (IC50 = 38 ng/mL)
                  * Low cytotoxicity (IC50 on HeLa cells = 2000 ng/mL, IC50 on P388 cells = 890 ng/mL)
                  * Also exhibit effect against Trypanosoma Congolense (sleeping sickness) and Plasmodium Falciparum (malaria)
                  * US provisional patent application filed

                  Possible Applications:
                  Lead compounds for antiprotozoal drugs

                  Full details Contact close
                • Therapeutic Peptide for Allergic DiseasesTherapeutic Peptide for Allergic Diseases
                    Preview
                    Description

                    The inventor has newly developed an inhibitory peptide of human mast cell activation for the treatment of allergic diseases. There are increasing evidences that mast cells from different species are functionally heterogeneous so that the known anti-allergic agents such as SCG and NS have much less effect on human mast cells compared to murine mast cells. Therefore, the proposed peptide which targets human IgE receptor (FceRIbeta) expressed on human mast cells can be a promising drug for the treatment of allergic diseases. Furthermore, the FceRIbeta is expressed exclusively on the surface of mast cells and basophils, suggesting the peptide has no potential side effect. Also, the cost is much lower than anti-IgE recombinant humanized monoclonal antibody, which is only drug that inhibits human mast cell activation but pretty expensive.

                    Features and Advantages
                    * 25-amino acid peptides (can be shortened to 17 amino acids)
                    * Recombinant cell-penetrating form of phosphorylated FcERI beta ITAM
                    * Inhibits IgE-dependent human mast cell activation by disturbing the interaction between a Src kinase Lyn and phosphorylated endogenous FceR1 beta ITAM
                    * Significantly inhibited IgE-dependent human mast cell activation in vitro
                    * Effectively inhibited hypersensitivity reactions in murine models in vivo
                    * PCT application filed

                    Possible Applications
                    * Human allergic diseases
                    - Allergic brochial asthma, atopic dermatitis, acute and chronic urticeria
                    - Food allergy, anaphylaxis, allergic rhinitis, vernal keratoconjunctivitis


                    The pdf file with more detailed information is available at
                    http://www.japantechnologygroup.com/seeds/JTGseeds_Therapeutic_Peptide.pdf

                    Full details Contact close